Immunovant (IMVT) Interest Expenses (2019)
Immunovant (IMVT) reported Interest Expenses of $376000.0 for Q4 2019, up 51.0% quarter-over-quarter from $249000.0 in Q3 2019.
Immunovant (IMVT) Interest Expenses (2019) Analysis & Trends
Immunovant has reported Interest Expenses for 1 years, with the latest figure at $376000.0 in Q4 2019.
- For the quarter ending Q4 2019, Interest Expenses changed N/A year-over-year to $376000.0; the trailing twelve-month figure through Sep 2020 stood at $376000.0 (up 51.0% YoY), and the FY2020 full-year result was $625000.0, changed N/A from the prior year.
- Interest Expenses for Q4 2019 stood at $376000.0, up from $249000.0 in the prior quarter.
- The five-year high for Interest Expenses was $376000.0 in Q4 2019, with the low at $249000.0 in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -5.50 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 61,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -332,000.00 |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -2,753.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -5.58 Mn |
| 10 | Immunovant | 5.71 Bn | 5.71 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 376,000.00 |
| Dec 31, 2019 | 376,000.00 |
| Sep 30, 2019 | 249,000.00 |
| Sep 30, 2019 | 249,000.00 |